@_ruchipatel
 Philadelphia, PA
Joined February 2020
  • Tweets209
  • Following205
  • Followers172
5Media
Ruchi Patel retweeted
Ruella Lab@RuellaLabJun 17
Ruella Lab is proud to announce that @MarcoRuella has won @BloodCancerUtd Greater Philadelphia Visionary of the Year! Thanks to all supporters to our campaign, YOU made a HUGE contribution to fight cancer! @PennMedicine
5
4
1
19
1,722
Ruchi Patel retweeted
Ruella Lab@RuellaLabAug 14
Excited to share our work in @NatureMedicine! @MarcoRuella @PennMedicine
Nature Medicine
@NatureMedicineAug 11
Analysis of longitudinal blood samples shows that #CD19 #CARTs can be detected at least 10 years post-treatment in patients with #lymphoma, with deeper profiling from a single patient showing that these CARTs have a dominant double negative activated effector memory-like phenotype. @MarcoRuella @ruellalab @pennmedicine @paruzzol nature.com/articles/s41591-0…

Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Nature Medicine - Analysis of longitudinal blood samples shows that CD19 CAR T cells can be detected at least 10 years after treatment in patients with lymphoma, with deeper profiling from a single...

nature.com
3
4
15
2,451
Honored to join the most recent cohort of Damon Runyon Fellows. I’m grateful to the Damon Runyon Cancer Research Foundation for supporting ambitious research projects and excited to join a community of inspiring young scientists. secure-web.cisco.com/1EMvwW-…
3
14
2,249
Excited to share that my second paper from graduate school is out now at Nature Genetics. We show that Enhancer-Promoter interactions can form de novo in the absence of loop extrusion. nature.com/articles/s41588-0…
3
32
1
122
11,225
Exciting news: EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models @Cancer_Cell @MarcoRuella @AlbertoCarturan @PuneethGuru_ @_ruchipatel @yunlin_zhang_ @guido_ghilardi and my stellar co-author Siena Nason cell.com/cancer-cell/abstrac…
1
7
18
922
Excited to share our latest work on bioRxiv! Using cell-cycle dynamics and NIPBL depletion, we show that long-range enhancer interactions can form de novo without loop extrusion. Alternative mechanisms, including LDB1 and YY1, may play key roles.biorxiv.org/content/10.1101/…

Cis-regulatory chromatin contacts form de novo in the absence of loop extrusion

NIPBL promotes chromatin loop extrusion by the cohesin complex until it stalls at convergently oriented CTCF sites, leading to the formation of structural loops. However, to what extent loop extrus...

biorxiv.org
3
13
1
67
7,700
cell.com/molecular-cell/full… Our paper is now online @MolecularCell. Architectural protein LDB1 drives enhancer connectivity independently of CTCF/cohesin!
3
20
104
13,323
Wild experience to have seen our story shared at the #ASH24 Plenary in San Diego by my wonderful co-lead @Shan_Liu_ ! Looking forward to further proving that we can enhance cancer treatment by modulating readily-actionable patient lifestyle factors.
Penn Medicine
@PennMedicine8 Dec 2024
A simple dietary supplement may provide a new approach to boost #CART cell function – hear more in the #ASH24 Plenary Session today. @MarcoRuella @MaayanLevy_Lab @PuneethGuru_ spr.ly/6015QKswz
1
5
13
1,356
Grateful to #ASH2024 for the chance to present our work on overcoming the absence of CD2:CD58 co-stimulation using an innovative PD1:iCD2 switch receptor. Thanks to my mentor @MarcoRuella and the @RuellaLab for their invaluable support. Excited to delve deeper into this approach!
6
1
13
1,070
Learn more about the exciting advances in blood cancer and benign hematology research that Penn Medicine and @PennCancer experts will be presenting at the @ASH_hematology Annual Meeting this weekend. #ASH24 spr.ly/6015txypB
5
15
1,429
#ASH24 Energy matters! Ketogenic Diet Enhances CAR T Cell Antitumor Function Via β-Hydroxybutyrate #CARTCell #TCell #tcellrx #immunotherapy @PennMedicine ash.confex.com/ash/2024/webp…
2
5
1
14
1,795
A simple dietary supplement may provide a new approach to boost #CART cell function – hear more in the #ASH24 Plenary Session today. @MarcoRuella @MaayanLevy_Lab @PuneethGuru_ spr.ly/6015QKswz
3
1
13
3,584
Very excited to share this work that could not have been done without the help of @RaisBahrami and @arnabguonc ! Big thank you to The Oncologist for this opportunity!
The Oncologist@OncJournal3 Sep 2024
High-sensitivity #ctDNA tests can be used to detect radiologically occult disease or minimal residual disease post-surgery & identify high-risk patients. This review summarizes current evidence, w/ focus on genitourinary tumors. @KartikPatel___ doi.org/10.1093/oncolo/oyae1…
1
1
6
538
Happy to share my thesis work, now online at bioRxiv. We show that LDB1 organizes Enhancer-Promoter interaction networks and can function independently of cohesin! biorxiv.org/content/10.1101/…

LDB1 establishes multi-enhancer networks to regulate gene expression

How specific enhancer-promoter pairing is established is still mostly unclear. Besides the CTCF/cohesin machinery, only a few nuclear factors have been studied for a direct role in physically...

biorxiv.org
1
30
1
79
16,846
The effectiveness of #CARTCellTherapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, according to research led by @PennCancer's Dr. @MarcoRuella. spr.ly/6012YGdWi
2
11
713
In a study published in @SciImmunology, @PennMedicine researchers identify #CD5 as an immune checkpoint protein & potential target of future cancer therapies ft. @MarcoRuella (@PennCancer) tinyurl.com/4nzzy3bs
4
11
1,023
Replying to @parkerici @UCLA @UCSF @cityofhope @DanaFarber
A discovery from PICI Investigators @Penn has revealed that deleting the CD5 gene in CAR T cells significantly enhances their antitumor activity across multiple cancer types, opening new avenues for more potent and effective immunotherapies. science.org/doi/10.1126/scii… (5/5)

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Deleting CD5 with CRISPR-Cas9 enhances T cell activation and proliferation, boosting their antitumor effects in multiple tumor models.

science.org
1
2
471
Ruchi Patel retweeted
ACIR
@ACIR_org1 Aug 2024
Patel et al. used the CRISPR-Cas9 system to ablate expression of the TCR-associated T cell inhibitory receptor CD5 from CAR T cells of several specificities and TCR-redirected T cells. bit.ly/4cnT9J7  @_ruchipatel  @MarcoRuella @PennMedicine
1
6
358
Genetic deletion of #CD5 in CAR T cells given to mice led to enhanced expansion, persistence, and anti-tumor effects against a range of preclinical solid and blood #cancer models. Read more in Science #Immunology: scim.ag/7LE
1
16
60
4,330
NEW -CD5 deletion enhances the antitumor activity of adoptive T cell therapies in vivo (liquid & solid cancer models) by enhancement of T signaling, cytotoxicity, and persistence. Stellar work by @_ruchipatel @MarcoRuella @PennMedicine @SciImmunology science.org/doi/10.1126/scii…

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Deleting CD5 with CRISPR-Cas9 enhances T cell activation and proliferation, boosting their antitumor effects in multiple tumor models.

science.org
1
6
1
39
2,090
Load more